Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by Marshall Wace LLP

Marshall Wace LLP reduced its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 53.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,348 shares of the company's stock after selling 25,703 shares during the period. Marshall Wace LLP's holdings in Janux Therapeutics were worth $1,197,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. Barclays PLC increased its position in shares of Janux Therapeutics by 496.5% in the third quarter. Barclays PLC now owns 174,061 shares of the company's stock valued at $7,907,000 after acquiring an additional 144,883 shares during the period. Virtu Financial LLC grew its stake in shares of Janux Therapeutics by 48.0% in the third quarter. Virtu Financial LLC now owns 7,463 shares of the company's stock worth $339,000 after purchasing an additional 2,419 shares during the last quarter. Franklin Resources Inc. increased its holdings in Janux Therapeutics by 64.5% during the 3rd quarter. Franklin Resources Inc. now owns 18,983 shares of the company's stock valued at $937,000 after purchasing an additional 7,442 shares during the period. Avanza Fonder AB bought a new position in Janux Therapeutics during the 4th quarter valued at approximately $139,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Janux Therapeutics by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock worth $596,000 after buying an additional 1,095 shares during the period. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Up 2.6 %

NASDAQ:JANX traded up $0.83 during midday trading on Friday, hitting $32.88. The stock had a trading volume of 825,257 shares, compared to its average volume of 848,137. The stock has a 50-day moving average of $29.80 and a 200 day moving average of $42.57. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of -28.10 and a beta of 3.27. Janux Therapeutics, Inc. has a one year low of $22.52 and a one year high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on JANX. Wedbush reaffirmed an "outperform" rating and issued a $76.00 target price (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. William Blair reissued an "outperform" rating on shares of Janux Therapeutics in a research report on Friday, January 10th. HC Wainwright restated a "buy" rating and set a $70.00 price target on shares of Janux Therapeutics in a research report on Monday, March 3rd. Finally, Scotiabank reduced their price target on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research note on Friday, February 28th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $95.25.

Insider Buying and Selling at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $42.29, for a total transaction of $140,994.86. Following the sale, the insider now directly owns 82,139 shares of the company's stock, valued at $3,473,658.31. This represents a 3.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ra Capital Management, L.P. purchased 110,206 shares of the stock in a transaction on Friday, March 7th. The shares were acquired at an average price of $31.02 per share, for a total transaction of $3,418,590.12. Following the transaction, the director now directly owns 10,141,287 shares of the company's stock, valued at $314,582,722.74. This represents a 1.10 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 13,335 shares of company stock worth $454,959. 29.40% of the stock is owned by corporate insiders.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.